Acesion Pharma Announces Positive Pre-Clinical Data for AP31969
COPENHAGEN, Denmark, May 15, 2023 /PRNewswire/ — Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces positive data from pre-clinical studies with AP31969, its second-generation oral SK channel inhibitor developed for chronic oral maintenance treatment to prevent AF recurrence. Acesion … Read more